ArticleCureus2025
Assessment of Albumin Therapy and Paracentesis Interval in Cirrhotic Patients With Recurrent Ascites: A Prospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimMany people with liver cirrhosis develop recurrent ascites that requires repeated treatments of large-volume paracentesis (LVP). This study aimed to determine whether intravenous albumin treatment extends the interval between paracentesis procedures, while also preventing paracentesis-induced circulatory dysfunction (PICD) and renal dysfunction among cirrhotic patients who experience recurrent ascites.
methodsThis prospective cohort study was carried out at a tertiary care hospital in Pakistan from April 2023 to August 2023, including 120 patients undergoing LVP treatment for cirrhosis were divided into two equal groups. OpenEpi version 3.0.0 (released 2013, developed by Andrew G. Dean, Kevin M. Sullivan, and Daniel G. Soe, Atlanta, GA, USA) was used for calculation. The 60 patients in Group A received albumin, while 60 in Group B received only saline. Over four months, outcomes were evaluated. The statistical analysis was performed using IBM SPSS Statistics for Windows, Version 26 (Released 2019; IBM Corp., Armonk, New York, United States).
resultsGroup A experienced a prolonged time interval between paracentesis treatments (18.2 vs. 11.1 days, p < 0.001) and a reduced occurrence of PICD (7 (11.7%) vs. 23 (38.3%), p = 0.001) and renal dysfunction (6 (10.0%) vs. 18 (30.0%), p = 0.008). The patients in Group A experienced reduced incidents of hospitalizations, together with emergency procedures. This highlighted the greater efficacy of albumin than saline.
conclusionUsing albumin in therapy decreased the risks of recurring fluid buildup in cirrhotic patients, as it helped in prolonging the time between repeated fluid removal procedures. However, due to a single-center approach, the generalizability of the results was limited. Nonetheless, albumin administration at the standardized intervals should become part of the therapeutic regimen because it ensures patients' safety and reduces the workload on medical staff.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.